大环内酯类抗菌药物治疗下呼吸道感染的临床药动学研究被引量：12

Clinical pharmacokinetics of macrolides antibiotics on treatment of lower respiratory tract infections

导出

摘要目的探讨大环内酯类抗菌药物的临床药动学特征,为临床治疗下呼吸道感染提供理论依据。方法选取2012年5月-2015年5月于医院接受治疗的下呼吸道感染患者162例作为研究对象,根据不同的治疗方案分成对照组和观察组,各81例,对照组采用复方甘草合剂+红霉素胶囊或克拉霉素进行治疗;观察组采用复方甘草合剂+红霉素胶囊+二代头孢抗菌药物进行治疗。结果对照组患者治疗后治愈率为53.09%,总有效率为91.36%;观察组患者治疗后治愈率为91.36%,总有效率为97.53%;两组感染患者的病原菌分布,差异无统计学意义;下呼吸道感染患者中,三类常见的大环内酯类抗菌药物的病原菌耐药性比较,阿奇霉素的耐药率明显低于罗红霉素,红霉素的耐药率高于罗红霉素,不同病原菌对同一类药物的的耐药率之间有一定差异,大环内酯类抗菌药物对革兰阳性菌和真菌作用比较弱。结论大环内酯类抗菌药物治疗下呼吸道感染的临床疗效明显,值得临床推广使用。 OBJECTIVE To explore the clinical pharmacokinetics of macrolides antibiotics so as to provide theoretical basis for clinical treatment of lower respiratory tract infections.METHODS A total of 162 patients with lower respiratory tract infections who were treated in the hospital from May 2012 to May 2015 were recruited as the study objects and divided into the control group and the observation group according to the treatment programs,with 81 cases in each group.The control group was treated with brown mixture plus erythromycin capsules or clarithromycin,while the observation group was given brown mixture plus erythromycin capsules plus second generation cephalosporins.RESULTS The cure rate was 53.09%in the control group after the treatment,91.36%in the observation group;the total effective rate of treatment was 91.36%in the control group,97.53%in the observation group.There was no significant difference in the distribution of pathogens causing the infections between the two groups of patients.As compared with the drug resistance rates of the pathogens to the three types of common macrolides antibiotics,the drug resistance rate was significantly lower to azithromycin than to roxithromycin.The drug resistance rate to the same type of antibiotic varied among the pathogens.The gram-positive bacteria and fungi were less resistant to the macrolides antibiotics.CONCLUSION The macrolides antibiotics can achieve significant clinical effect on treatment of the lower respiratory tract infections and are worthy to be promoted in the hospital.

作者孙非侯杰密芳郭辉苏长英

机构地区山东枣庄矿业集团公司中心医院呼吸科

出处《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第12期2688-2690,共3页 Chinese Journal of Nosocomiology

基金山东省卫生厅科研基金资助项目(SW-2010B027)

关键词大环内酯类抗菌药物下呼吸道感染临床动力学疗效 Macrolide Antibiotic Lower respiratory tract infection Clinical kinetics Efficacy

分类号 R978.15 [医药卫生—药品]

引文网络
相关文献

参考文献13

1窦维嘉,宋志芳.首选口服大环内酯类抗菌药物门诊治疗下呼吸道感染疗效评价[J].中国全科医学,2014,17(1):105-109. 被引量：13
2叶惠韶,张常然,吴文辉,叶东平.下呼吸道感染的抗菌药物应用分析[J].中华医院感染学杂志,2012,22(21):4876-4878. 被引量：2
3Polso AK,Lassiter JL,Nagel JL.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review[J].J Clin Pharm Ther,2014,39(6):584-608.
4唐仕强,蒋华,申琰军.小剂量红霉素治疗婴幼儿支原体肺炎的探索[J].儿科药学杂志,2013,19(5):20-22. 被引量：9
5Akaike H,Miyashita N,Kubo M,et al.In vitro activities of 11antimicrobial agents against macrolide-resistant Mycoplasma pneumoniae isolates from pediatric patients:results from a multicenter surveillance study[J].Jpn J Infect Dis,2012,65(6):535-538.
6孙恩萍,尹育.红霉素联合阿奇霉素序贯治疗小儿支原体肺炎临床疗效分析[J].中国医药科学,2013,3(17):96-97. 被引量：5
7Yoshida K,Okimoto N,Kishimoto M,et al.Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis[J].Infect Chemother,2011,17(5):678-685.
8Kakinuma Y,Maeda Y,Mason C,et al.Molecular characterisation of the quinolone resistance-determining regions(QRDR)including gyrA,gyrB,parC and parE genes in Streptococcus pneumoniae[J].Br J Biomed Sci,2012,69(3):123-125.
9Ubukata K.Mechanisms of beta-lactam and quinolone resistance in Haemophilus influenzae[J].Nihon Rinsho,2012,70(2):247-250.
10Adachi F,Yamamoto A,Takakura KI,et al.Occurrence of fluoroquinolones and fluoroquinolone-resistance genes in the aquatic environment[J].Sci Total Environ,2013,444(5):508-514.

二级参考文献41

1杨景毅,程书权.红霉素类药物在某些非细菌性传染病中的应用进展[J].国际病毒学杂志,2008,15(4). 被引量：2
2刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量：788
3社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量：3057
4沈晓明,王卫平.儿科学[M].第七版.北京:人民卫生出版社,2008.153.
5中华医学会儿科学分会呼吸学组.儿童社区获得性肺炎管理指南(试行).中华儿科杂志,2007,2(45):2-3.
6冯益真.实用小儿呼吸病学[M].第二版.北京:中国协和医科大学出版社,2006: 149.
7K Ishida,M Kaku, K Irifune, et al. In vitro and in vivo activitiesof macrolides against Mycoplasma pneumoniae [ J ]. AntimicrobAgents Chemother, 1994,38(4) : 790-798.
8Houck PM, MacLehose RF, Niederman MS, et aL Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and1997 [J]. Chest, 2001, 119 (5): 1420 -1426.
9Ngeow YF, Suwanjutha S, Chantarojanasriri T, et al. An Asia study on the prevalence of atypical respiratory pathogens in community acquired pneumonia [J]. Int J Infect Dis, 2005, 9 (3) : 144 -153.
10Ramsdell J, Narsavage GL, Fink JB. Management of community - ac- quired pneumonia in the home: An American College of Chest Physi- cians clinical position statement [J]. Chest, 2005, 127 (5) : 1752 - 1763.